ArticleJournal of cosmetic dermatology2026
The Association of Acne Vulgaris and Disease Severity With Serum Amyloid A1 and Insulin Levels.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcne vulgaris is a chronic inflammatory disease involving multiple factors such as increased sebum production, follicular hyperkeratinization, microbial colonization, and inflammation. Serum amyloid A1 (SAA1), an acute phase protein, and insulin, a hormone linked to metabolic and inflammatory pathways, may play significant roles in acne pathogenesis.
objectiveThis study aimed to evaluate SAA1 and insulin levels in patients with acne vulgaris and to investigate their relationship with disease severity and scar formation.
methodsA total of 72 acne vulgaris patients [13 males, 59 females; median age 22 (19-34) years] and 66 age-similar healthy controls [27 males, 39 females; median age 22 (18-38) years] were included. Acne severity was assessed using the Global Acne Grading System (GAGS), and scar severity was evaluated by the Global Scale for Acne Scar Severity. SAA1 and insulin levels were measured via ELISA from fasting blood samples. Additionally, anthropometric measurements and biochemical parameters were recorded.
resultsA total of 138 participants were included, with 72 acne vulgaris patients and 66 healthy controls. The groups were age-similar, though a higher female proportion was observed in the acne group. SAA1 levels were significantly higher in acne patients (p = 0.045), whereas insulin levels did not differ significantly (p = 0.902). LDL, triglycerides, and total cholesterol were significantly lower in the acne group (p = 0.003, p = 0.045, p = 0.023, respectively). SAA1 levels did not significantly correlate with acne severity (p = 0.052) or scar severity (p = 0.09). However, LDL and total cholesterol showed weak negative correlations with both acne severity and scar severity.
conclusionElevated SAA1 in acne vulgaris patients suggests that SAA1 may serve as a novel biomarker for assessing inflammation in acne. Further large-scale studies are needed to explore therapeutic implications targeting inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.